Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Company PIC

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Fineline Cube Aug 27, 2026
Company Drug PIC

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

Fineline Cube Aug 27, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Company Drug

Changchun High‑Tech Secures NMPA Approval for GenSci139 Bispecific ADC in Advanced Solid Tumors

Fineline Cube Oct 21, 2025

Changchun High‑Tech (SHE: 000661) announced today that its wholly‑owned subsidiary, GenSci (GeneScience Pharmaceutical), has received...

Company Drug

Salubris Shares Promising JK06 ADC Results from ESMO 2025 Clinical Presentation

Fineline Cube Oct 21, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced today that its U.S. subsidiary, Salubris Biotherapeutics,...

Company Deals

Advaccine Biotechnology Announces Private Placement of Up to 2.2 Million Shares to Raise RMB 300 Million for Microneedle & Vaccine Development

Fineline Cube Oct 21, 2025

Advaccine Biotechnology (NEEQ: 874055) today disclosed a private placement offering of no more than 2,203,200 shares...

Company Drug

Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC

Fineline Cube Oct 21, 2025

Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it...

Company Deals

Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108

Fineline Cube Oct 21, 2025

Samsung Bioepis Co., Ltd. today announced a strategic, worldwide partnership with Phrontline Biopharma to jointly develop,...

Company Drug

Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors

Fineline Cube Oct 20, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced today that the U.S. Food and Drug Administration...

Company Drug

CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer

Fineline Cube Oct 20, 2025

CARsgen Therapeutics Holdings Limited (HKG: 2171) today disclosed interim data from the Phase Ib registrational study...

Company Drug

CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer

Fineline Cube Oct 20, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that JSKN003, a HER2‑bi‑epitope targeted antibody‑drug conjugate (ADC)...

Company Drug

Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC

Fineline Cube Oct 20, 2025

Akeso Inc. (HKG: 9926) today disclosed the results of its global first‑in‑class bispecific antibody ivonescimab...

Company Drug

Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion

Fineline Cube Oct 20, 2025

Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...

Company Deals

China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply

Fineline Cube Oct 20, 2025

China Isotope & Radiation Corporation (HKG: 1763) announced today that it has signed a Memorandum...

Company Deals

Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares

Fineline Cube Oct 20, 2025

Wuhan Healthgen Biotechnology Corp. (SHA: 688765) today announced that the Shanghai Stock Exchange has approved...

Company Drug

Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer

Fineline Cube Oct 20, 2025

Alphamab Oncology (HKG: 9966) today disclosed the first interim data from its Phase III study evaluating...

Company Deals

Fosun Kairos Secures Series A Financing to Propel Cell‑Therapy Expansion

Fineline Cube Oct 20, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund...

Company Drug

Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC

Fineline Cube Oct 20, 2025

Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...

Company Drug

Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer

Fineline Cube Oct 20, 2025

Eli Lilly & Company (NYSE: LLY) today disclosed the long‑term benefits of abemaciclib in hormone‑receptor‑positive...

Others

Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC

Fineline Cube Oct 20, 2025

Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted...

Company Deals

Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros

Fineline Cube Oct 20, 2025

Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license...

Company Deals

Boehringer Ingelheim & AimedBio Announce Global ADC Collaboration to Target Broad‑Spectrum Cancers

Fineline Cube Oct 20, 2025

Boehringer Ingelheim today disclosed a worldwide collaboration and licensing agreement with AimedBio to develop a...

Company Deals

Pregene Partners with Kite to Pioneer Next-Generation In Vivo Therapies

Fineline Cube Oct 20, 2025

Shenzhen Pregene Biopharma Co., Ltd. has entered into a License and Collaboration Agreement with Kite,...

Posts pagination

1 … 138 139 140 … 713

Recent updates

  • Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked
  • HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%
  • CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer
  • Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
  • Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Company Drug

CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer

Company

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.